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The present study was designed to evaluate different doses of ellagic acid (EA) in vivo in rats for its potential to modulate hepatic
phases I, II, and antioxidant enzymes. EA (10 or 30mg/kg/day, intragastrically) was administered for 14 consecutive days, and
activity, protein, and mRNA levels were determined. Although the cytochrome P450 (CYP) 2B and CYP2E enzyme activities
were decreased significantly, the activities of all other enzymes were unchanged with the 10mg/kg/day EA. In addition, western-
blot and qRT-PCR results clearly corroborated the above enzyme expressions. On the other hand, while the NAD(P)H:quinone
oxidoreductase 1 (NQO1), catalase (CAT), glutathione peroxidase (GPX), and glutathione S-transferase (GST) activities were
increased significantly, CYP1A, 2B, 2C, 2E, and 19 enzyme activities were reduced significantly with 30mg/kg/day EA. In addition,
CYP2B, 2C6, 2E1, and 19 protein and mRNA levels were substantially decreased by the 30mg/kg/day dose of EA, but the CYP1A
protein, and mRNA levels were not changed. CYP3A enzyme activity, protein and mRNA levels were not altered by neither 10 nor
30mg/kg/day ellagic acid.These results indicate that EA exerts a dose-dependent impact on themetabolismof chemical carcinogens
and drugs by affecting the enzymes involved in xenobiotics activation/detoxification and antioxidant pathways.
1. Introduction
Ellagic acid (EA) is one of the important components of
fruits and vegetables [1] and has been shown to possess
numerous anticarcinogenic and antimutagenic properties
towards various carcinogens [1–7]. Several mechanisms have
been proposed to explain the broad antimutagenic and
anticarcinogenic effects of EA [8–13]. One of the mech-
anisms proposed involves inhibition of cytochrome P450
(CYP450) enzymes [8]. CYP450 enzymes are widely known
for their role in the metabolism of drugs and other foreign
compounds. Thus, modulation of this enzyme system can
influence the metabolism of xenobiotics, producing effects
of pharmacological and toxicological importance. A number
of naturally occurring flavonoids have been shown to mod-
ulate the CYP450 system by the activation or inhibition of
these enzymes [14]. Multiple P450 isozymes show different
substrate specificities and affinities toward both endogenous
and exogenous compounds. Among these P450s, CYP1A, 2B,
2C, 2E, and 3A subfamilies have received a great deal of
attention in recent years because of their ability to metabolize
various pharmaceutical and carcinogenic agents [15–17]. It
is well established that CYP1A and CYP2E enzymes are
mainly involved in carcinogen metabolism while CYP3A,
CYP2B, and CYP2C enzymes aremainly responsible for drug
metabolism.
Aromatase represents a crucial enzyme of estrogen
biosynthesis, and increased expression of aromatase has
been observed in breast cancer tissue [18]. Flavonoids and
isoflavones are structurally similar to the endogenous estra-
diol and possess both estrogenic and antiestrogenic activities
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[19]. Previous studies suggest that ellagic acid has potential for
the prevention of estrogen-responsive breast cancers [20, 21].
Another possible mechanism for the broad chemopro-
tective and antioxidant effects of EA might involve the
induction of phase II and antioxidant enzymes. GSTs have a
considerably important role in the detoxification of carcino-
gens [22]. NQO1 prevents quinine redox cycling and lowers
levels of electrophilic quinines [23]. Hence, the inductions of
GST and NQO1 by flavonoids are possibly associated with
cancer chemopreventive effects. The present study is, to our
knowledge, the first study analyzing the effect of EA onNQO1
activity, mRNA, and protein levels in rat.
Although there are individual studies examining the
effect of EA on several enzymes, no study has evaluated the
alteration of so many enzymes simultaneously with different
dose of EA. Therefore, the present study was undertaken to
observe the overall simultaneous changes following in vivo
treatment with different dose of EA by investigating changes
in the activity,mRNA, andprotein levels of specific rat hepatic
P450s, phase II, and antioxidant enzymes at once.
2. Material and Methods
2.1. Chemicals. The following chemicals were purchased
from Sigma-Aldrich Chemical Company (St Louis, Mis-
souri, USA): ellagic acid, acrylamide, aniline, anti-rabbit
IgG-HRP conjugate, bovine serum albumin (BSA), Folin
phenol reagent, glycerol, glycine, HEPES, 𝛽-NADPH, phe-
nol, caffeine, TRIS, PMSF, potassium dihydrogen phosphate,
dipotassium hydrogen phosphate, sodium dodecyl sulfate
(SDS), and sodium potassium tartrate. Anti-rat CYP1A1,
CYP2B, CYP2C6, CYP2E1, CYP3A1, and CYP19 antibodies
were from Abcam (Abcam PLC, Cambridge, UK). All other
chemicals and solvents were obtained from commercial
sources at the highest grade of purity available.
2.2. Animals and Treatment. Healthy maleWistar rats, about
12 weeks old andweighing 200–250 g, were obtained from the
University Animal House.They were housed in small cages at
an ambient temperature of 22±1∘C, on a 12 h light/dark cycle,
and a standard pellet diet and distilled water were available
without restriction. All experimental procedures with the
animals were performed under appropriate regimes with vet-
erinary services within the licensed projects (PAUHADEK-
2009-007).
After being acclimatized for 1 week, the rats were ran-
domized and divided into three groups. Ellagic acid was
given intragastrically to two experimental groups (15 rats per
group) in a dose of 10mg/kg/day (T10) and 30mg/kg/day
(T30) dissolved in DMSO, respectively. Control (15 rats)
rats only received a vehicle (DMSO). The doses used were
chosen to be similar to the doses used in previous studies
in the literature [24–26]. The animals were treated for 14
consecutive days. At the end of the experimental period
and following 16 h of fasting, blood was collected by heart
puncture and the rats were killed; the livers were removed,
rinsed with cold physiological saline, and stored at −80∘C
until analyzed.
2.3. Preparations of S1.5, Cytosolic, and Microsomal Frac-
tion. Tissues were homogenized in a 4 part homogeniza-
tion solution (1.15% KCl containing 3mM EDTA, 0.5mM
APMSF, 0.3mM 𝜀-aminocaproic acid, 0.15mM butylated
hydroxytoluene, and 0.025% Triton X-100) using a tissue
homogenizer with a Teflon pestle at 4∘C. Subcellular fractions
(S1.5, cytosolic, microsomal) of rat tissues were prepared by
standard differential centrifugation with calcium aggregation
as described by [27]. The amount of protein in individual
fractions was measured using BCA [28] with BSA as the
standard.
2.4. Enzyme Assays. Serum aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) activities
were determined with an autoanalyzer using audit di-
agnostics AST and ALT. The microsomal cytochrome
P450-dependent aniline 4-hydroxylase (A4H) activities
of rat microsomes were determined by measuring the
quantity of p-aminophenol formed, as described by [29].
Aminopyrene N-demethylase (APND), erythromycin N-
demethylase (ERND) and caffeine N-demethylase (C3ND),
n-nitrosodimethylamine N-demethylase (NDMA), ethyl-
morphine N-demethylase (EmND), and benzphetamine
N-demethylase (BPND) activities were determined by
measuring the quantity of formaldehyde formed, according
to the method of [30] and modified by [31]. Ethoxyresorufin
O-deethylase (EROD), and methoxyresorufin O-demethyl-
ase (MROD), benzyloxyresorufin O-demethylase (BROD),
pentoxyresorufin O-demethylase (PROD) activities were
assayed as described by [15]. Dibenzylfluorescein-O-
debenzylase (DBFOD) activities were assayed as described
by [32]. Rat liver NQO1 enzyme activity was determined
according to the method of [33]. Glutathione S-transferase
(GST) activities were assayed as described by [34]. Catalase
(CAT) and glutathione peroxidase (GPx) activities were
determined by [35, 36], respectively.
2.5. Gel Electrophoresis andWestern Blotting. SDS-PAGE and
western blotting were performed as described previously
[15]. Briefly, 120𝜇g protein samples were separated on 8.5%
polyacrylamide gels using the discontinuous buffer system
of [37]. Proteins were transferred to a nitrocellulose mem-
brane by the iBlot dry blotting system (20V, 12min), using
iBlot gel transfer stacks. Following transfer, the membranes
were blocked using 5% nonfat dry milk in TBST (20mM
Tris-HCl, pH 7.4, 400mM NaCl, and 0.1% (v/v) Tween20)
for 60min, and incubated with mouse polyclonal anti-rat
CYP1A1, CYP2B, CYP2C6, CYP2E1, CYP3A1, or CYP19
antibodies (diluted 1 : 1000 in blocking solution) for 120min
at room temperature.Themembranes were then washed with
TBST (3 × 5min), incubated with the secondary antibody
(HRP-conjugated anti-rabbit IgG at a 1 : 5000 or 1 : 10000
dilution) for 60min and again washed with TBST (3 ×
5min). Proteins were detected using SuperSignal West Pico
Chemoluminescent Substrate (Pierce, Rockford, IL, USA),
and bands were visualized and recorded using GelQuant
Image Analysis Software in a DNR LightBIS Pro Image
Analysis System (DNR Bio-Imaging Systems Ltd., Jerusalem,
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Figure 1: The expression levels of CYP1A protein and mRNA in
control rats and rats treated with EA. Treatments were carried
out as described in Section 2. Lanes 1–10, rat liver microsome
sample. Wells have equal amount of protein. (a) Representative
immunoblot analysis of liver microsomal CYP1A proteins in sample
and experimental groups, using rabbit anti-rat CYP1A IgG for 1 h at
room temperature. Proteins were detected using chemoluminescent
substrate for 3 minutes, and bands were visualized and recorded
using a DNR LightBIS Pro Image Analysis System. (b) Comparison
of CYP1A protein and mRNA levels among experimental groups.
The bar graphs represent the mean intensity of the bands obtained
from western blot and/or qRT-PCR results. Results are presented
as the mean from three independent experiments and expressed as
relative mean ± standard deviation.
Israel). Protein bands were quantified using Scion Image
Version Beta 4.0.2 software.
2.6. RNA Isolation and qRT-PCR of CYP mRNAs. Total RNA
was extracted from 100mg rat livers using TRIzol reagent.
Extracted RNA was quantified spectrophotometrically at
260/280 nm, and the integrity was checked using 1% agarose
gel. For cDNA synthesis, 2.5 𝜇g of RNAwas incubated at 70∘C
for 10 minutes with 0.5𝜇g of oligo (dT). After 5min on ice,
50U Moloney murine leukemia virus reverses transcriptase,
1mM dNTPs and 5X reaction buffer were added to the
previous mixture and incubated at 42∘C for 60min. The
reaction was stopped by heating the mixture to 70∘C for
10min, and the cDNA was stored at −80∘C for further use.
qRT-PCR assay was performed by using gene specific
primers. The oligosequences used as forward and reverse
Table 1: Blood serumAST andALT enzyme activities in control and
EA-treated rats.
AST
Change
fold
AST
Change
foldUnit/min/mg
protein
Unit/min/mg
protein
Control 1.53 ± 0.12 — 1.33 ± 0.19 —
10mg/kg EA 1.55 ± 0.16 — 1.38 ± 0.21 —
30mg/kg EA 1.54 ± 0.21 — 1.34 ± 0.12 —
primers for rat CYP450 isozymes were based on those
reported in [38, 39]. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and 𝛽-actin were used as a housekeeping
gene. The PCR amplification was done using Power SYBR
Green PCR master mix (Roche Applied Science, Basel,
Switzerland) and 500 nmol/L of forward and reverse primers
for each gene, for which the final primer concentration
was 125 nmol/L each. Quantitative PCR was done using a
Light Cycler 1.5 Instrument (Roche Applied Science, Basel,
Switzerland). The PCR conditions were as follows: DNA
polymerase activation at 95∘C for 15 minutes, followed by 45
cycles at 95∘C for 10 seconds, 54–57∘C annealing (depending
on the gene) for 5 seconds, and 72∘C for 30 seconds. All gene
analyses were done at least three times.
2.7. Statistical Analysis. Statistical analyses were performed
using the Minitab 13 statistical software package (Minitab,
Inc., State College, PA, USA). All results were expressed
as means including their Standard Error of Means (SEMs).
Comparison between groups was performed using Student’s
t-test, and 𝑃 < 0.05 was selected as the level required
for statistical significance. Statistical comparisons between
three groups were assessed by one-way analysis of variance
(ANOVA). When F ratios were significant (𝑃 < 0.05),
one-way ANOVA was followed by Tukey’s Post hoc test for
comparisons of multiple group means.
3. Results
Control and treated rats showed no significant differences in
food consumption or body weight, (data not shown) after
intragastric delivery of the EA to the animals at two different
doses (T10 and T30).
As shown in Table 1, blood serumAST and ALT activities
were not changed when compared to the control rats. As
presented in Table 2, hepatic 1A1-associated EROD and 1A2-
associatedMRODorC3NDactivities were decreased 11% and
13% or 40% in T30 treated rats, respectively, when compared
to controls.
The effect of the EA onCYP2B-associated BPND, EmND,
BROD, and PROD activities is presented in Table 2. EA
treatment at T10 or T30 for 14 consecutive days caused a
statistically significant (𝑃 < 0.05) 13%, 10%, 15%, and 10% or
55%, 38%, 23%, and 30% decrease in these activities in the
liver, respectively.
CYP2E-associated A4H and NDMA activities in control
and EA-treated rats are given in Table 2. As can be seen, A4H
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Table 2: Changes of activities in liver of EA-treated rats.
Control 10mg/kg EA Change (%) 30mg/kg EA Change (%)
EROD (pmol resorufin/min/mg prot.) 6.24 ± 2.23 6.53 ± 1.52 — 5.58 ± 3.97 11 ↓
MROD (pmol resorufin/min/mg prot.) 8.39 ± 2.49 8.31 ± 1.07 — 7.33 ± 3.40 13 ↓
C3ND (nmol HCHO/min/mg prot.) 0.40 ± 0.14 0.39 ± 0.02 — 0.24 ± 1.27∗ 40 ↓
EmND (nmol HCHO/min/mg prot.) 1.96 ± 0.35 1.78 ± 0.85 10 ↓ 1.22 ± 0.09∗ 38 ↓
BPND (nmol HCHO/min/mg prot.) 1.47 ± 0.40 1.29 ± 0.61 13 ↓ 0.662 ± 0.308∗ 55 ↓
BROD (pmol resorufin/min/mg prot.) 2.61 ± 0.86 2.23 ± 1.20 15 ↓ 2.03 ± 1.39∗ 23 ↓
PROD (pmol resorufin/min/mg prot.) 6.51 ± 1.99 5.89 ± 0.907 10 ↓ 4.60 ± 2.71∗ 30 ↓
APND (nmol HCHO/min/mg prot.) 0.339 ± 0.037 0.331 ± 0.031 — 0.154 ± 0.013∗ 55 ↓
A4H (nmol p-aminophenol/min/mg prot.) 0.344 ± 0.014 0.245 ± 0.08 28 ↓ 0.145 ± 0.08∗ 58 ↓
NDMA (nmol HCHO/min/mg prot.) 0.405 ± 0.01 0.298 ± 0.11 26 ↓ 0.114 ± 0.17∗ 56 ↓
ERND (nmol HCHO/min/mg prot.) 0.117 ± 0.027 0.124 ± 0.021 — 0.085 ± 0.045∗ 28 ↓
DBFOD (nmol fluorescein/min/mg prot.) 6.66 ± 0.138 6.15 ± 0.427 — 5.12 ± 1.84∗ 24 ↓
NQO1 (nmol/min/mg prot.) 184 ± 10.25 183 ± 9.49 — 541 ± 23.18∗ 194 ↑
GST-CDNB (nmol/min/mg prot.) 559 ± 56.71 561 ± 87.11 — 835 ± 13.08∗ 49 ↑
GST-DCNB (nmol/min/mg prot.) 12.99 ± 4.29 12.90 ± 8.15 — 18.45 ± 3.93∗ 42 ↑
GST-EA (nmol/min/mg prot.) 10.35 ± 1.61 10.32 ± 1.11 — 13.79 ± 3.22∗ 33 ↑
CAT (nmol/min/mg prot.) 9.33 ± 0.29 9.25 ± 0.33 — 15.37 ± 0.33∗ 64 ↑
GPX (nmol/min/mg prot.) 0.048 ± 0.004 0.05 ± 0.007 — 0.103 ± 0.003∗ 114 ↑
∗Significantly different from the respective control value, 𝑃 < 0.05.
and NDMA activities were reduced 58% and 56% with the
T30 treatment. Similarly, EA treatment at T10 reduced 28%
and 26% with respect to the control.
The effect of the EA on CYP2C6-associated APND,
CYP3A-associated ERND, and CYP19-associated DBFOD
activity is presented in Table 2. EA treatment at T30 caused
a statistically significant 55%, 28%, and 24% decrease in
CYP2C6, CYP3A, and CYP19 activities in the liver, respec-
tively.
GSTs activities in control and EA-treated rats are given
in Table 2. GST activities towards three different substrates,
namely, CDNB, DCNB, and EA were increased 49%, 42%,
and 33% (𝑃 < 0.05) in the T30 treated group. Furthermore,
treatment of rats with T30 dose caused 194%, 64%, and 114%
increases in NQO1, CAT, and GPX activities, respectively,
when compared to the control values (Table 2).
The activation of catalytic activities was generally consis-
tent with the protein levels of related CYP isoforms in rat liver
microsomes that were prepared from control and EA-treated
rats (Figures 1–6). The densitometric scanning of western
blot results showed that hepatic CYP1A and CYP3A were not
significantly changed in the T10 or T30 treated rats relative to
the control animals (Figures 1 and 5).
The densitometric scanning of western blot results
showed that hepatic CYP2B protein level was decreased 51%
and 38% as a result of two different doses of EA treatments.
Moreover, T10 and T30 treatments caused a 53% and 32%
reduction of the CYP2E protein level (Figures 2 and 4).
Although CYP2C and CYP19 protein levels were reduced
with T30 treatment, it was not at a significant level (Figures 3
and 6).
The effect of EA on themRNA levels of CYP isozymeswas
also determined throughout in this study.The relative CYP1A
and CYP3A mRNA levels were not changed significantly
in the EA-treated rats as compared to the control animals
(Figures 1 and 5). CYP2E level was decreased significantly
79% and 31% in T10 and T30 treated rats, respectively
(Figure 4). In addition, CYP2B level was reduced 76% and
39% as a result of two different doses of EA-treated rats
relative to the controls (Figure 2). CYP2C level was decreased
49% significantly in EA-treated rats at T30, respectively
(Figure 3). Similar to the changes at protein level, CYP19
mRNA was decreased but not significantly (Figure 6).
4. Discussion
Alterations in the cellular metabolism of xenobiotics are
the most important mechanisms that play a vital role dur-
ing chemical-induced carcinogenicity. Therefore, the use of
dietary antioxidants is an important preventive method to
minimize the pathological and toxic effects associated with
xenobiotics [8, 10, 14]. In this context, this study is carried out
to examine the dose-dependent effects of EA on specific P450
forms and also on selected phase II and antioxidant enzymes
in rat liver.
Plasma AST and ALT, alone or in combination, are
primarily recommended for the assessment of hepatocellular
injury in rodents and nonrodents in nonclinical studies.They
are sensitive markers for drug-induced liver damage, and
the elevated activities of these marker enzymes in plasma
are indicative of cellular leakage and loss of the functional
integrity of cell membranes in the liver [40]. Treatment with
EA at different doses (T10 and T30) caused no changes in the
activities of these marker enzymes in plasma when compared
with the control group. Therefore, EA, at these doses, can be
used in preventive or complementary medicine with safety
precautions and within the scope of the methods employed
in public health.
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Figure 2: The expression levels of CYP2B protein and mRNA in
control rats and rats treated with EA. Treatments were carried
out as described in Section 2. Lanes 1–10, rat liver microsome
sample. Wells have equal amount of protein. (a) Representative
immunoblot analysis of liver microsomal CYP2B proteins in sample
and experimental groups, using rabbit anti-rat CYP2B IgG for 1 h at
room temperature. Proteins were detected using chemoluminescent
substrate for 3 minutes, and bands were visualized and recorded
using a DNR LightBIS Pro Image Analysis System. (b) Comparison
of CYP2B protein and mRNA levels among experimental groups.
The bar graphs represent the mean intensity of the bands obtained
from western blot and/or qRT-PCR results. Results are presented
as the mean from three independent experiments and expressed as
relative mean ± standard deviation. ∗𝑃 < 0.05, compared with the
control group.
Among all cytochrome P450 isoforms, CYP1A holds
priority due to its role in the metabolism of carcinogens,
mutagens, and environmental pollutants. This CYP is the
primary P450 involved in the conversion of outstanding
carcinogens to the electrophilic metabolites and is known
to be induced by its substrates such as benzopyrene. In
this study, CYP1A1/CYP1A2-associated enzyme activities,
EROD, MROD, and C3ND were all decreased as a result
of T30 treatment, consistent with the previous findings
of [41]. Although EA treatment resulted in a significant
reduction in CYP1A1/CYP1A2-associated enzyme activities,
hepatic CYP1A1 protein and mRNA levels were found not
to be changed with EA treatments. EA inhibited CYP1A
enzymes directly, without an alteration of its gene and protein
expression, and the in vivo effect depends to a great degree
on the concentration of this compound in rat liver. Hence,
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Figure 3: Effect of EA on the expressions of CYP2C protein
and mRNA in rat liver microsomes. Rats were treated with EA
injection and liver microsomes prepared as described in Section 2.
(a) The microsomal proteins were separated by SDS—PAGE, and
western blot analysis was performed as described in Section 2. Each
lane contained 100mg microsomal protein. Proteins were detected
using chemoluminescent substrate for 3 minutes, and bands were
visualized and recorded using a DNR LightBIS Pro Image Analysis
System. (b) The expression level of CYP2C mRNAs in control rats
and rats treated with EA. Treatments were carried out as described
in Section 2. The bar graph represents the mean intensity of the
bands obtained from western blot and/or qRT-PCR results. Results
are presented as the mean from three independent experiments
and expressed as relative mean ± standard deviation. ∗𝑃 < 0.05,
compared with the control group.
the results have demonstrated that EA is able to abrogate
chemical carcinogenicity most likely by offsetting CYP1A
activity and possibly by the scavenging of the electrophilic
metabolite.
CYP2E1 is important in the field of toxicology and
carcinogenesis, and it also has a role in drugmetabolism [42].
It also plays a vital role in the generation of oxidative stress
during alcohol-induced toxicity [43]. Intake of the EA both
at doses, T10 and T30, for 14 consecutive days decreased A4H
and NDMA activities in the liver. In addition, densitometric
analysis of western blots showed that the hepatic CYP2E1
protein level was decreased significantly in the EA-treated
rats relative to the control animals. Similarly, [44] showed
6 BioMed Research International
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Figure 4: Effect of EA on the expressions of CYP2E protein
and mRNA in rat liver microsomes. Rats were treated with EA
injection and liver microsomes prepared as described in Section 2.
(a) The microsomal proteins were separated by SDS—PAGE, and
western blot analysis was performed as described in Section 2. Each
lane contained 100mg microsomal protein. Proteins were detected
using chemoluminescent substrate for 3 minutes, and bands were
visualized and recorded using a DNR LightBIS Pro Image Analysis
System. (b) The expression level of CYP2E mRNAs in control rats
and rats treated with EA. Treatments were carried out as described
in Section 2. The bar graph represents the mean intensity of the
bands obtained from western blot and/or qRT-PCR results. Results
are presented as the mean from three independent experiments
and expressed as relative mean ± standard deviation. ∗𝑃 < 0.05,
compared with the control group.
that EA has an inhibitory effect on NDMA. Consistent with
protein levels, administration of the EA had also decreased
the CYP2E1 mRNA level. Since the regulation of CYP2E1
expression is complex, involving transcriptional, posttran-
scriptional, and posttranslational events with polymorphism
playing a role [45], the observed mRNA decrease resulting
from EA treatment could be either transcriptional or post-
transcriptional, which remains to be elucidated. Hence, no
matter what the mechanism is, EA administration might
decrease the carcinogenesis by inhibiting CYP2E1 and reduce
reactive oxygen species by affecting the metabolic pathways
of alcohol.
Cytochrome 2B, 2C, and 3A enzymes participate in a
wide array of metabolism of drugs. Treatment with the EA
caused a significant decrease in CYP2B-associated EmND,
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Figure 5: Effect of EA on the expressions of CYP3A protein
and mRNA in rat liver microsomes. Rats were treated with EA
injection and liver microsomes prepared as described in Section 2.
(a) The microsomal proteins were separated by SDS—PAGE, and
western blot analysis was performed as described in Section 2. Each
lane contained 100mg microsomal protein. Proteins were detected
using chemoluminescent substrate for 3 minutes, and bands were
visualized and recorded using a DNR LightBIS Pro Image Analysis
System. (b) The expression level of CYP3A mRNAs in control rats
and rats treated with EA. Treatments were carried out as described
in Section 2. The bar graph represents the mean intensity of the
bands obtained from western blot and/or qRT-PCR results. Results
are presented as the mean from three independent experiments and
expressed as relative mean ± standard deviation.
BPND, BROD, and PROD activities as well as CYP2B protein
and mRNA. Moreover, CYP2C-associated APND activity
was decreased significantly with T30 dose of EA. Also,
CYP2C protein and mRNA level were decreased with the
same dose. Similarly, EA-treatment caused inhibitory effect
in CYP3A-associated ERND activity in rat liver microsomes.
As previously shown with CYP3A or CYP2C activities [46,
47], EA, which is an antioxidant found in large quantities
in pomegranate juice, displayed a probably nonmechanism-
based inhibitory effect for CYP3A andCYP2C activities in rat
liver microsomes. Thus, drug interactions are fairly likely to
occur if EA supplements are taken simultaneouslywith drugs.
The aromatase enzyme, which converts androgen to
estrogen, plays a key role particularly in breast carcinogenesis.
CYP19-associated enzyme activities, DBFOD,were decreased
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Figure 6: The expression levels of CYP19 protein and mRNA in
control rats and rats treated with EA. Treatments were carried
out as described in Section 2. Lanes 1–10, rat liver microsome
sample. Wells have equal amount of protein. (a) Representative
immunoblot analysis of liver microsomal CYP19 proteins in sample
and experimental groups, using rabbit anti-rat CYP19 IgG for 1 h at
room temperature. Proteins were detected using chemoluminescent
substrate for 3 minutes, and bands were visualized and recorded
using a DNR LightBIS Pro Image Analysis System. (b) Comparison
ofCYP19 protein andmRNA levels among experimental groups.The
bar graphs represent the mean intensity of the bands obtained from
western blot and/or qRT-PCR results. Results are presented as the
mean from three independent experiments and expressed as relative
mean ± standard deviation.
as a result of T30 treatment. In addition, CYP19 protein and
mRNA levels were reduced with T30 to a lesser extent than
the activities. Therefore, the observed inhibition resulting
from EA treatment could be neither transcriptional nor
translational and remains to be elucidated. Taken together
with the results of previous reports [20] and the results of the
current study, it may be suggested that EA intake may be a
viable strategy for the chemoprevention of breast cancer.
Some of the anticancer effects of dietary polyphenols are
related, at least partly, to their indirect antioxidant activities
[48–51]. For example, the enhancement of GPX, catalase,
NQO1, GSTs, and/or phase II enzyme activities by polyphe-
nols could help the detoxification of carcinogenic agents.
Hence, the induction of these enzyme activities by flavonoids
is possibly associated with cancer chemopreventive effects.
In this study, EA treatment caused an increase in GSTs,
NQO1, GPX, and CAT activities in rat liver microsomes.
Similarly, the induction of liver GSTs, NQO1, and CAT
enzyme activities by flavonoids such as genistein, daidzein,
flavone, rutin, quercitrin, myricetin, and kaempferol was
reported in recent studies [52–56]. These observations may
be of importance in view of the potential use of EA both as
potent anticancer agents as well as chemopreventive agents.
5. Conclusion
In this study, the different doses of EA did not produce the
same effects. While the lower dose of EA (10mg/kg/day) was
not effective because its concentration might not have been
enough to reach to the site of action and quench all free
radicals generated, the higher dose of EA (30mg/kg/day)
was good enough to be effective. In conclusion, the dose-
dependent suppression of CYP1A, CYP2E, and CYP19 and
the induction of GSTs, NQO1, GPX, and CAT enzymes
suggest anticancer as well as chemopreventive roles for EA
while reductions in CYP2B, 2C, and 3A explain potential
drug interactions.
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